{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T17:08:54Z","timestamp":1780506534319,"version":"3.54.1"},"reference-count":12,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:p>Meropenem\/vaborbactam is a combination antibiotic with a carbapenem and a carbapenemase inhibitor typically reserved for extensively drug-resistant bacterial infections, such as carbapenem-resistant Enterobacterales (CRE). Meropenem\/vaborbactam is approved by the United States Food and Drug Administration for use in adults for complicated urinary tract infections, whereas data in the pediatric population are limited. This case series described the use of meropenem\/vaborbactam in 2 pediatric patients, ages 11 and 15, with intraabdominal abscesses from CRE. Both patients had clinically improved after the initiation of meropenem\/vaborbactam and reported no complications during their follow-up appointments after the completion of their antibiotic courses. These cases demonstrate the safe and effective use of meropenem\/vaborbactam in these 2 pediatric patients. Although meropenem\/vaborbactam successfully treated both patients\u2019 infections, additional data are needed in this population to determine the safety profile and optimal use for pediatric patients.<\/jats:p>","DOI":"10.5863\/1551-6776-30.2.263","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:48:26Z","timestamp":1745246906000},"page":"263-267","source":"Crossref","is-referenced-by-count":1,"title":["Meropenem\/Vaborbactam in Pediatrics: 2 Cases of CRE Intraabdominal Infection"],"prefix":"10.5863","volume":"30","author":[{"given":"Ugene","family":"Sano","sequence":"first","affiliation":[{"name":"Departments of Pharmacy (US, RM, SS) and Pediatric Infectious Disease (UH), Cooperman Barnabas Medical Center, Livingston, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Meyers","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy (US, RM, SS) and Pediatric Infectious Disease (UH), Cooperman Barnabas Medical Center, Livingston, NJ"},{"name":"Ernest Mario School of Pharmacy (RM), Rutgers University, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uzma","family":"Hasan","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy (US, RM, SS) and Pediatric Infectious Disease (UH), Cooperman Barnabas Medical Center, Livingston, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Smoke","sequence":"additional","affiliation":[{"name":"Departments of Pharmacy (US, RM, SS) and Pediatric Infectious Disease (UH), Cooperman Barnabas Medical Center, Livingston, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"(9)","key":"i2331-348X-30-2-263-b01","series-title":"Antimicrob Agents Chemother","first-page":"e00567\u201317","article-title":"Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae","volume":"61","author":"Castanheira","year":"2017","unstructured":"Castanheira M, Huband MD, Mendes RE, et al. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2017; 61(9):e00567\u201317."},{"issue":"(2)","key":"i2331-348X-30-2-263-b02","series-title":"Clin Infect Dis","first-page":"187","article-title":"Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum \u03b2-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","unstructured":"Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the treatment of extended-spectrum \u03b2-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis. 2022;75(2):187\u2013212."},{"key":"i2331-348X-30-2-263-b03","article-title":"Healthcare-associated infections: Table P8. Percent of CLABSI pathogens that were resistant to selected antimicrobials and classified as \u201curgent\u201d or \u201cserious\u201d antimicrobial resistant threats, by location type, pediatrics, 2018-2021","unstructured":"Centers for Disease Control and Prevention. Healthcare-associated infections: Table P8. Percent of CLABSI pathogens that were resistant to selected antimicrobials and classified as \u201curgent\u201d or \u201cserious\u201d antimicrobial resistant threats, by location type, pediatrics, 2018-2021. Accessed September 13, 2023. https:\/\/www.cdc.gov\/nhsn\/hai-report\/data-tables-pediatric\/table-p8.html"},{"key":"i2331-348X-30-2-263-b04","article-title":"Healthcare-associated infections: Table P9. Percent of CAUTI pathogens that were resistant to selected antimicrobials and classified as \u201curgent\u201d or \u201cserious\u201d antimicrobial resistant threats, pediatrics, 2018-2021","unstructured":"Centers for Disease Control and Prevention. Healthcare-associated infections: Table P9. Percent of CAUTI pathogens that were resistant to selected antimicrobials and classified as \u201curgent\u201d or \u201cserious\u201d antimicrobial resistant threats, pediatrics, 2018-2021. Accessed September 13, 2023. https:\/\/www.cdc.gov\/nhsn\/hai-report\/data-tables-pediatric\/table-p9.html"},{"key":"i2331-348X-30-2-263-b05","article-title":"Healthcare-associated infections: Table P10. Percent of SSI pathogens that were resistant to selected antimicrobials and classified as \u201curgent\u201d or \u201cserious\u201d antimicrobial resistant threats for high-volume surgical categories, pediatrics, 2018-2021","unstructured":"Centers for Disease Control and Prevention. Healthcare-associated infections: Table P10. Percent of SSI pathogens that were resistant to selected antimicrobials and classified as \u201curgent\u201d or \u201cserious\u201d antimicrobial resistant threats for high-volume surgical categories, pediatrics, 2018-2021. Accessed September 13, 2023. https:\/\/www.cdc.gov\/nhsn\/hai-report\/data-tables-pediatric\/table-p10.html"},{"key":"i2331-348X-30-2-263-b06","article-title":"Healthcare-associated infections","unstructured":"Centers for Disease Control and Prevention. Healthcare-associated infections. Accessed February 4, 2024. https:\/\/www.cdc.gov\/hai\/organisms\/cre\/cre-clinicians.html#:\u223c:text=Healthcare%2Drelated%20risk%20factors%20include,cephalosporins%2C%20fluoroquinolones%2C%20and%20vancomycin"},{"issue":"(12)","key":"i2331-348X-30-2-263-b07","series-title":"Pharmacotherapy","first-page":"e87","article-title":"Pharmacokinetics of the meropenem component of meropenem-vaborbactam in the treatment of KPC-producing Klebsiella pneumoniae bloodstream infection in a pediatric patient","volume":"38","author":"Hanretty","year":"2018","unstructured":"Hanretty AM, Kaur I, Evangelista AT, et al. Pharmacokinetics of the meropenem component of meropenem-vaborbactam in the treatment of KPC-producing Klebsiella pneumoniae bloodstream infection in a pediatric patient. Pharmacotherapy. 2018;38(12):e87\u2013e91."},{"issue":"(11)","key":"i2331-348X-30-2-263-b08","series-title":"Pediatr Pulmonol","first-page":"2990","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient","volume":"55","author":"Gainey","year":"2020","unstructured":"Gainey AB, Burch AK, Brownstein MJ, et al. Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient. Pediatr Pulmonol. 2020;55(11):2990\u20132994."},{"key":"i2331-348X-30-2-263-b09","series-title":"Antimicrob Agents Chemother","first-page":"e02097\u201316","article-title":"Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections","volume":"61","author":"Shields","year":"2017","unstructured":"Shields RK, Chen L, Cheng S, et al. Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections. Antimicrob Agents Chemother. 2017:61:e02097\u201316."},{"key":"i2331-348X-30-2-263-b10","series-title":"Antimicrob Agents Chemother","first-page":"e01551\u201318","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient","volume":"63","author":"Athans","year":"2018","unstructured":"Athans V, Neuner EA, Hassouna H, et al. Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-resistant Klebsiella pneumoniae bacteremia and abscess in a liver transplant recipient. Antimicrob Agents Chemother. 2018:63:e01551\u201318."},{"issue":"(3)","key":"i2331-348X-30-2-263-b11","series-title":"Antibiotics (Basel)","first-page":"421","article-title":"Mechanisms of action of carbapenem resistance","volume":"11","author":"Aurilio","year":"2022","unstructured":"Aurilio C, Sansone P, Barbarisi M, et al. Mechanisms of action of carbapenem resistance. Antibiotics (Basel). 2022;11(3):421."},{"key":"i2331-348X-30-2-263-b12","series-title":"Updated September 28, 2023","article-title":"Dose-finding, pharmacokinetics, and safety of VABOMERE in pediatric subjects with bacterial infections (TANGOKIDS). ClinicalTrials.gov identifier: NCT02687906","unstructured":"Melinta Therapeutics, LLC. Dose-finding, pharmacokinetics, and safety of VABOMERE in pediatric subjects with bacterial infections (TANGOKIDS). ClinicalTrials.gov identifier: NCT02687906. Updated September 28, 2023. Accessed December 23, 2023. https:\/\/clinicaltrials.gov\/study\/NCT02687906#more-information"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/2\/article-p263.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/2\/article-p263.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/2\/article-p263.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:48:27Z","timestamp":1745246907000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/2\/article-p263.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":12,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-30.2.263","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"value":"2331-348X","type":"electronic"},{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}